NewsletterJan | 21 | 2025
The journal Nature recently published The History of Alzheimer’s Disease, with a timeline from 1906 – 2024. This chart maps major developments that have helped shape current research on Alzheimer's disease. Three key discoveries from McCance Center Director Dr. Rudy Tanzi’s lab are featured in the chronology in 1987,1995 and 2008.
1987: The discovery of mutations in the gene encoding APP (Amyloid precursor protein) that are linked to some cases of familial Alzheimer's disease.
1995: Highlights the identification of the presenilin 1 and presenilin 2 genes as the most common cause of early-onset Alzheimer’s disease.
2008: Researchers find evidence that inflammation and the immune system play a role in the development of Alzheimer’s disease.
A randomized three-year clinical trial recently released shows fish oil high in omega-3 fatty acids provides statistically significant benefit for those genetically predisposed to Alzheimer’s. McCance Center’s Dr. Gene Bowman is senior corresponding author.
The McCance Center has launched an ambitious program to prevent Alzheimer’s disease (AD) – “The Pre-AD Initiative” (Prediction and Prevention of Alzheimer’s Disease).
Researchers have learned more about how increased levels of an enzymatic protein called HDAC6 connects to the onset of harmful brain changes in Alzheimer’s disease (AD) and identified a potential treatment strategy.
Jonathan Rosand, MD, MSC, presented the McCance Center’s strategy, strengths and progress and the Brain Care Score at the Science Summit of the 78th United Nations General Assembly meetings in New York City.
The goal of REACH-ICH is to explore how social determinants of health (SDOH) affect participation in a BP management program throughout ICH recovery.
New findings offer strong support for developing irisin as a therapeutic target for Alzheimer’s disease treatment and prevention.
Our mission is to reduce suffering and maximize human potential through better brain health for all.
